CN105263964A - 抗-TNF-α/CXCL10双靶向抗体及其应用 - Google Patents

抗-TNF-α/CXCL10双靶向抗体及其应用 Download PDF

Info

Publication number
CN105263964A
CN105263964A CN201480029427.2A CN201480029427A CN105263964A CN 105263964 A CN105263964 A CN 105263964A CN 201480029427 A CN201480029427 A CN 201480029427A CN 105263964 A CN105263964 A CN 105263964A
Authority
CN
China
Prior art keywords
antibody
amino acid
variable domain
chain variable
tnf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480029427.2A
Other languages
English (en)
Chinese (zh)
Inventor
姜欣濉
朴昭炫
宋永旭
申己澈
李恩荣
李恩奉
朴荣祐
朴范赞
李东熙
金东辰
尹善河
李基世
李炫周
金京珍
金熙赞
刘奭镐
张明熙
张世佚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Metabolic Engineering Laboratories Co Ltd
Original Assignee
Metabolic Engineering Laboratories Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabolic Engineering Laboratories Co Ltd filed Critical Metabolic Engineering Laboratories Co Ltd
Publication of CN105263964A publication Critical patent/CN105263964A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201480029427.2A 2013-05-22 2014-05-22 抗-TNF-α/CXCL10双靶向抗体及其应用 Pending CN105263964A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
KR20130057762 2013-05-22
KR20130057475 2013-05-22
KR10-2013-0057475 2013-05-22
KR10-2013-0057762 2013-05-22
PCT/KR2014/004579 WO2014189306A1 (ko) 2013-05-22 2014-05-22 항 ＴＮＦ-α/ＣＸＣＬ10 이중 타겟 항체 및 그의 용도

Publications (1)

Publication Number Publication Date
CN105263964A true CN105263964A (zh) 2016-01-20

Family

ID=51933801

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480029427.2A Pending CN105263964A (zh) 2013-05-22 2014-05-22 抗-TNF-α/CXCL10双靶向抗体及其应用

Country Status (11)

Country Link
US (1) US10087248B2 (https=)
EP (1) EP3000827B1 (https=)
JP (1) JP2016520595A (https=)
KR (1) KR101671955B1 (https=)
CN (1) CN105263964A (https=)
AU (1) AU2014269287B2 (https=)
BR (1) BR112015029224A2 (https=)
CA (1) CA2913118A1 (https=)
HK (1) HK1223112A1 (https=)
PH (1) PH12015502601A1 (https=)
WO (1) WO2014189306A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114432502A (zh) * 2021-12-31 2022-05-06 中山大学附属第八医院（深圳福田） 一种负载op3-4多肽、抗cxcl9抗体的水凝胶及其制备方法与应用

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2769282C2 (ru) 2016-06-20 2022-03-30 Кимаб Лимитед Анти-PD-L1 и IL-2 цитокины
EP3630836A1 (en) * 2017-05-31 2020-04-08 Elstar Therapeutics, Inc. Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
US10633458B2 (en) * 2018-04-10 2020-04-28 Y-Biologics Inc. Cell engaging binding molecules
WO2019197979A1 (en) * 2018-04-10 2019-10-17 Y-Biologics Inc. Cell engaging binding molecules
KR102088789B1 (ko) * 2018-06-20 2020-03-13 인하대학교 산학협력단 항 TNF/IFN scFv-Fc 이중 표적 항체 및 이의 이용
KR102323342B1 (ko) 2019-04-26 2021-11-08 주식회사 와이바이오로직스 IL-17A 및 TNF-α에 특이적으로 결합하는 이중표적 항체
KR102385046B1 (ko) 2020-08-24 2022-04-13 에스큐엔지니어링(주) 드론에 탈부착 점검장치를 이용한 다목적 구조물 검사장치
CN117836318A (zh) * 2021-03-31 2024-04-05 加利福尼亚大学董事会 用于降解靶蛋白的双特异性结合剂-配体融合物
KR102357756B1 (ko) 2021-05-14 2022-02-09 유한회사 서해항공방제 드론을 이용한 유해 조수 및 곤충 방제장치 및 그를 구비하는 드론

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1504752A (zh) * 1996-02-09 2004-06-16 ������ʵ���ң���Ľ�����޹�˾ 体外抑制人TNFα活性的方法
CN101370525A (zh) * 2005-08-19 2009-02-18 艾博特公司 双重可变结构域免疫球蛋白及其用途
US20100047239A1 (en) * 2005-08-19 2010-02-25 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050053600A1 (en) 2003-09-09 2005-03-10 Lane Thomas E. Methods for treating rheumatoid arthritis
CN101189339A (zh) * 2005-03-22 2008-05-28 美得思达健康有限公司 诊断和治疗心血管疾病的递送系统和方法
NZ595225A (en) * 2005-05-16 2013-05-31 Abbott Biotech Ltd Use of tnf inhibitor for treatment of erosive polyarthritis
WO2006138690A2 (en) * 2005-06-17 2006-12-28 Abbott Laboratories Improved method of treating degenerative spinal disorders
JP2012228248A (ja) * 2005-08-19 2012-11-22 Abbott Lab 二重可変ドメイン免疫グロブリン及びその使用
US20090148905A1 (en) * 2007-11-30 2009-06-11 Claire Ashman Antigen-binding constructs
CA2785907A1 (en) * 2009-12-29 2011-07-28 Emergent Product Development Seattle, Llc Ron binding constructs and methods of use thereof
RU2654567C2 (ru) * 2011-10-11 2018-05-21 Дженентек, Инк. Улучшенная сборка биспецифических антител
KR20130121601A (ko) 2012-04-27 2013-11-06 주식회사에이앤알쎄라퓨틱스 인간 항 ｃｘｃｌ－１０ 항체 및 이를 포함하는 류마티스 관절염 치료용 조성물

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1504752A (zh) * 1996-02-09 2004-06-16 ������ʵ���ң���Ľ�����޹�˾ 体外抑制人TNFα活性的方法
CN101370525A (zh) * 2005-08-19 2009-02-18 艾博特公司 双重可变结构域免疫球蛋白及其用途
US20100047239A1 (en) * 2005-08-19 2010-02-25 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114432502A (zh) * 2021-12-31 2022-05-06 中山大学附属第八医院（深圳福田） 一种负载op3-4多肽、抗cxcl9抗体的水凝胶及其制备方法与应用
CN114432502B (zh) * 2021-12-31 2023-02-03 中山大学附属第八医院（深圳福田） 一种负载op3-4多肽、抗cxcl9抗体的水凝胶及其制备方法与应用

Also Published As

Publication number Publication date
EP3000827A4 (en) 2016-08-24
CA2913118A1 (en) 2014-11-27
EP3000827A1 (en) 2016-03-30
EP3000827B1 (en) 2020-04-22
WO2014189306A1 (ko) 2014-11-27
HK1223112A1 (en) 2017-07-21
US20160108118A1 (en) 2016-04-21
US10087248B2 (en) 2018-10-02
BR112015029224A2 (pt) 2017-09-19
JP2016520595A (ja) 2016-07-14
AU2014269287B2 (en) 2016-08-25
AU2014269287A1 (en) 2015-12-10
PH12015502601A1 (en) 2016-02-29
KR20150010919A (ko) 2015-01-29
WO2014189306A8 (ko) 2015-12-03
KR101671955B1 (ko) 2016-11-07

Similar Documents

Publication Publication Date Title
CN105263964A (zh) 抗-TNF-α/CXCL10双靶向抗体及其应用
CN109937212B (zh) B7-h3抗体、其抗原结合片段及其医药用途
JP6883591B2 (ja) 抗ヒトインターロイキン−１７ａモノクローナル抗体、その製造方法及び使用
JP5259423B2 (ja) ドメイン抗体構築物
CN119735681A (zh) 优化的抗tl1a抗体
CN103261412B (zh) 抗人ccr7抗体、杂交瘤、核酸、载体、细胞、医药组合物和抗体固定化担载体
JP2008532936A (ja) インターロイキン−１７ｆ抗体及び他のｉｌ−１７ｆシグナル伝達拮抗物質並びにそれらの使用
JP2009525031A5 (https=)
WO2020119728A1 (zh) 抗人白细胞介素5(il-5)单克隆抗体及其应用
US20240166720A1 (en) Bioengineered immunomodulatory fusion protein compositions
TWI801425B (zh) Il-5 抗體、其抗原結合片段及醫藥用途
CN112996815B (zh) 人pd-l1抗体
WO2020108463A1 (zh) 人源化抗人ox40单克隆抗体及其制备方法和用途
US12460010B2 (en) Antibodies that bind TNFRSF25
KR20250117442A (ko) TNF-α 및 IL-17A를 표적하는 이중특이적 융합 단백질 및 이의 용도
CN101896502A (zh) 抗人TNFα单抗、分子进化及其应用
WO2018101425A1 (ja) 抗ｔｌｒ９抗体、医薬組成物及びキット
CN116710484A (zh) Wars中和抗体及其用途
WO2024141921A1 (en) Tumour necrosis factor alpha domain antibody
WO2026086930A1 (zh) Tl1a结合分子及其应用
WO2024255683A1 (zh) 抗bdca2抗体
CN121930341A (zh) Tl1a结合分子及其应用
HK40045762A (en) Human pd-l1 antibodies
HK40009319B (en) B7-h3 antibody, antigen-binding fragment thereof and medical use thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20160120